Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Anxiety and related disorders are the most common mental conditions affecting the North American population. Despite their established efficacy, first-line antidepressant treatments are associated with significant side effects, leading many afflicted individuals to seek alternative treatments. Cannabis is commonly viewed as a natural alternative for a variety of medical and mental health conditions. Currently, anxiety ranks among the top five medical symptoms for which North Americans report using medical marijuana. However, upon careful review of the extant treatment literature, the anxiolytic effects of cannabis in clinical populations are surprisingly not well-documented. The effects of cannabis on anxiety and mood symptoms have been examined in healthy populations and in several small studies of synthetic cannabinoid agents but there are currently no studies which have examined the effects of the cannabis plant on anxiety and related disorders. In light of the rapidly shifting landscape regarding the legalization of cannabis for medical and recreational purposes, it is important to highlight the significant disconnect between the scientific literature, public opinion, and related policies. The aim of this article is to provide a comprehensive review of the current cannabis treatment literature, and to identify the potential for cannabis to be used as a therapeutic intervention for anxiety, mood, and related disorders. Searches of five electronic databases were conducted (PubMed, MEDLINE, Web of Science, PsychINFO, and Google Scholar), with the most recent in February 2017. The effects of cannabis on healthy populations and clinical psychiatric samples will be discussed, focusing primarily on anxiety and mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Rauch, S. L., Shin, L. M., & Phelps, E. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.004 · Cited by 1,397
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 2×
“Unfortunately, this treatment is not widely available and is often associated with significant cost to the patient (Katzman et al., 2014).”
BackgroundSelf-citationThe endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · cited 1×
“…also suggested that MDD can also occur with alterations in the endocannabinoid system (Aso, Ozaita, Serra, & Maldonado, 2011; Gorzalka & Hill, 2011; Mechoulam & Parker, 2013) and preclinical studies show that genetic deletion of CB1 receptors results in depressive-like behaviors (Aso et al., 2011;…”
BackgroundBergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 2×
“The observed power used in the statistical analysis of the anxiety VAMS factor and in the negative self-evaluation scale were 0.996 and 0.881, respectively (Bergamaschi et al., 2011).”
MethodInfluentialCrippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421
Continuity of antidepressant treatment for adults with depression in the United States
Olfson, M., Marcus, S. C., Tedeschi, M., & Wan, G. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.101 · Cited by 392
Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear
Chhatwal, J. P., Davis, M., Maguschak, K. A., & Ressler, K. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300655 · Cited by 376
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364
Research works printed but not linked: 77
- Ablon, 1974, High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients, American Journal of Psychiatry, 131, 448, 10.1176/ajp.1974.131.4.448 · DOI
- Ashton, 1981, The seed and the soil: Effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man, British Journal of Clinical Pharmacology, 12, 705, 10.1111/j.1365-2125.1981.tb01294.x · DOI · Paper page
- Aso, 2011, Genes differentially expressed in CB 1 knockout mice: Involvement in the depressive-like phenotype, European Neuropsychopharmacology, 21, 11, 10.1016/j.euroneuro.2010.06.007 · DOI
- Bandelow, 2008, World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-First revision, World Journal of Biological Psychiatry, 9, 248, 10.1080/15622970802465807 · DOI · Paper page
- Bhattacharyya, 2010, Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology, Neuropsychopharmacology, 35, 764, 10.1038/npp.2009.184 · DOI · Paper page
- Blass, 2008, Treating depression with cannabinoids (Cannabinoids 3)
- Blessing, 2015, Cannabidiol as a potential treatment for anxiety disorders, Neurotherapeutics, 12, 825, 10.1007/s13311-015-0387-1 · DOI · Paper page
- Bonn-Miller, 2014, Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD, Drug and alcohol Dependence, 136, 162, 10.1016/j.drugalcdep.2013.12.008 · DOI · Paper page
- Bonn-Miller, 2007, Marijuana use motives: Concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers, Addictive Behaviors, 32, 49, 10.1016/j.addbeh.2006.03.018 · DOI · Paper page
- Bossong, 2013, The endocannabinoid system and emotional processing: A pharmacological fMRI study with∆ 9-tetrahydrocannabinol, European Neuropsychopharmacology, 23, 1687, 10.1016/j.euroneuro.2013.06.009 · DOI
- Cameron, 2014, Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation, Journal of Clinical Psychopharmacology, 34, 559, 10.1097/JCP.0000000000000180 · DOI · Paper page
- Cerdá, 2012, Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence, Drug and Alcohol Dependence, 120, 22, 10.1016/j.drugalcdep.2011.06.011 · DOI · Paper page
- Cheung, 2010, Anxiety and mood disorders and cannabis use, American Journal of Drug and Alcohol Abuse, 36, 118, 10.3109/00952991003713784 · DOI · Paper page
- Cooper, 2013, Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers, Neuropsychopharmacology, 38, 1984, 10.1038/npp.2013.97 · DOI
- Cougle, 2011, Posttraumatic stress disorder and cannabis use in a nationally representative sample, Psychology of Addictive Behaviors, 25, 554, 10.1037/a0023076 · DOI · Paper page
- Crippa, 2009, Cannabis and anxiety: A critical review of the evidence, Human Psychopharmacology: Clinical and Experimental, 24, 515, 10.1002/hup.1048 · DOI · Paper page
- Das, 2013, Cannabidiol enhances consolidation of explicit fear extinction in humans, Psychopharmacology, 226, 781, 10.1007/s00213-012-2955-y · DOI · Paper page
- Degenhardt, 2012, Extent of illicit drug use and dependence, and their contribution to the global burden of disease, Lancet, 379, 55, 10.1016/S0140-6736(11)61138-0 · DOI · Paper page
- Downey, 2013, The effects of cannabis and alcohol on simulated driving: Influences of dose and experience, Accident Analysis and Prevention, 50, 879, 10.1016/j.aap.2012.07.016 · DOI · Paper page
- D'Souza, 2004, The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis, Neuropsychopharmacology, 29, 1558, 10.1038/sj.npp.1300496 · DOI · Paper page
- D'souza, 2015, Medical marijuana: Is the cart before the horse, JAMA, 313, 2431, 10.1001/jama.2015.6407 · DOI
- Feingold, 2015, The association between cannabis use and mood disorders: A longitudinal study, Journal of Affective Disorders, 172, 211, 10.1016/j.jad.2014.10.006 · DOI · Paper page
- Fusar-Poli, 2009, S39-01 Distinct effects of D9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing, European Psychiatry, 24, S206, 10.1016/S0924-9338(09)70439-0 · DOI
- Gates, 2014, The effects of cannabinoid administration on sleep: A systematic review of human studies, Sleep Medicine Reviews, 18, 477, 10.1016/j.smrv.2014.02.005 · DOI
- Gibbs, 2015, Cannabis use and mania symptoms: A systematic review and meta-analysis, Journal of Affective Disorders, 171, 39, 10.1016/j.jad.2014.09.016 · DOI · Paper page
- Glass, 1981, Single-dose study of nabilone in anxious volunteers, Journal of Clinical Pharmacology, 21, 383S, 10.1002/j.1552-4604.1981.tb02618.x · DOI · Paper page
- Gomes, 2011, Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 434, 10.1016/j.pnpbp.2010.11.027 · DOI
- Gorzalka, 2011, Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 1575, 10.1016/j.pnpbp.2010.11.021 · DOI
- Grant, 2011, Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: A pilot study, Psychopharmacology, 218, 493, 10.1007/s00213-011-2347-8 · DOI
- Grant, 2016, Associations of posttraumatic stress disorder symptoms with marijuana and synthetic cannabis use among young adult US Veterans: A pilot investigation, Journal of Studies on Alcohol and Drugs, 77, 509, 10.15288/jsad.2016.77.509 · DOI
- Greer, 2014, PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program, Journal of Psychoactive Drugs, 46, 73, 10.1080/02791072.2013.873843 · DOI · Paper page
- Grotenhermen, 2003, Pharmacokinetics and pharmacodynamics of cannabinoids, Clinical Pharmacokinetics, 42, 327, 10.2165/00003088-200342040-00003 · DOI · Paper page
- Gruber, 1996, Do patients use marijuana as an antidepressant, Depression, 4, 77, 10.1002/(SICI)1522-7162(1996)4:2<77::AID-DEPR7>3.0.CO;2-C · DOI · Paper page
- Gruber, 2012, Marijuana impacts mood in bipolar disorder: A pilot study, Mental Health and Substance Use, 5, 228, 10.1080/17523281.2012.659751 · DOI
- Hasin, 2015, Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: Results from annual, repeated cross-sectional surveys, Lancet Psychiatry, 2, 601, 10.1016/S2215-0366(15)00217-5 · DOI · Paper page
- Hemming, 1993, Effective treatment of Tourette's syndrome with marijuana, Journal of Psychopharmacology, 7, 389, 10.1177/026988119300700411 · DOI · Paper page
- Henquet, 2006, Cannabis use and expression of mania in the general population, Journal of Affective Disorders, 95, 103
- Ilaria, 1981, Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis, Current Therapeutic Research, Clinical and Experimental, 29, 943
- Jetly, 2015, The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study, Psychoneuroendocrinology, 51, 585, 10.1016/j.psyneuen.2014.11.002 · DOI · Paper page
- Johnson, 2016, Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD, Journal of Affective Disorders, 190, 439, 10.1016/j.jad.2015.10.048 · DOI
- Karniol, 1974, Cannabidiol interferes with the effects of Δ 9-tetrahydrocannabinol in man, European Journal of Pharmacology, 28, 172, 10.1016/0014-2999(74)90129-0 · DOI · Paper page
- Kessler, 2005, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication, Archives of General Psychiatry, 62, 593, 10.1001/archpsyc.62.6.593 · DOI · Paper page
- Kevorkian, 2015, Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample, Psychology of addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors, 29, 633, 10.1037/adb0000110 · DOI
- Kotin, 1973, Δ9-Tetrahydrocannabinol in depressed patients, Archives of General Psychiatry, 28, 345, 10.1001/archpsyc.1973.01750330041007 · DOI · Paper page
- Ksir, 2016, Cannabis and psychosis: A critical overview of the relationship, Current Psychiatry Reports, 18, 1, 10.1007/s11920-015-0657-y · DOI · Paper page
- Lee, 2009, Anxiolytic effect of an oral cannabinoid in patients with anxiety, European Journal of Pain, 13, S200
- Lin, 2016, Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample, Addictive Behaviors, 61, 99, 10.1016/j.addbeh.2016.05.015 · DOI · Paper page
- Machado Rocha, 2008, Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis, European Journal of Cancer Care, 17, 431, 10.1111/j.1365-2354.2008.00917.x · DOI · Paper page
- Martín-Sánchez, 2009, Systematic review and meta-analysis of cannabis treatment for chronic pain, Pain Medicine, 10, 1353, 10.1111/j.1526-4637.2009.00703.x · DOI · Paper page
- Martin-Santos, 2012, Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers, Current Pharmaceutical Design, 18, 4966, 10.2174/138161212802884780 · DOI · Paper page
- Martyn, 1995, Nabilone in the treatment of multiple sclerosis, Lancet, 345, 579, 10.1016/S0140-6736(95)90485-9 · DOI
- Mashiah, 2012, Medical cannabis as treatment for chronic combat PTSD: Promising results in an open label pilot study
- Müller-Vahl, 1998, Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome, Acta Psychiatrica Scandinavica, 98, 502, 10.1111/j.1600-0447.1998.tb10127.x · DOI · Paper page
- Muller-Vahl, 1999, Treatment of tourette's syndrome with delta-9-tetrahydrocannbinol, American Journal of Psychiatry, 156, 495, 10.1176/ajp.156.3.495 · DOI
- National Academies of Sciences, Engineering, and Medicine, 2017, The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research, 289
- Passie, 2012, Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence, Drug Testing and Analysis, 4, 649, 10.1002/dta.1377 · DOI · Paper page
- Phillips, 2010, Pharmacological treatment of painful HIV-associated sensory neuropathy: A systematic review and meta-analysis of randomised controlled trials, PLoS One, 5, e14433, 10.1371/journal.pone.0014433 · DOI · Paper page
- Pond, 1948, Psychological effects in depressive patients of the marihuana homologue synhexyl, Journal of Neurology, Neurosurgery and Psychiatry, 11, 271, 10.1136/jnnp.11.4.271 · DOI
- Rabinak, 2014, Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans, Neurobiology of Learning and Memory, 113, 125, 10.1016/j.nlm.2013.09.009 · DOI · Paper page
- Regelson, 1976, The Pharmacology of Marihuana, 763
- Reinarman, 2011, Who are medical marijuana patients? Population characteristics from nine California assessment clinics, Journal of Psychoactive Drugs, 43, 128, 10.1080/02791072.2011.587700 · DOI · Paper page
- Reznik , I. 2011 Medical cannabis use in post-traumatic stress disorder: A naturalistic observational study Abstract presented at the cannabinoid conference. Bonn, Germany 8 10
- Roitman, 2014, Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder, Clinical Drug Investigation, 34, 587, 10.1007/s40261-014-0212-3 · DOI · Paper page
- Roy-Byrne, 2015, Are medical marijuana users different from recreational users? The view from primary care, American Journal on Addictions, 24, 599, 10.1111/ajad.12270 · DOI
- Sandyk, 1988, Marijuana and Tourette's syndrome, Journal of Clinical Psychopharmacology, 8, 444, 10.1097/00004714-198812000-00021 · DOI
- Schindler, 2008, Improvement in refractory obsessive compulsive disorder with dronabinol, American Journal of Psychiatry, 165, 536, 10.1176/appi.ajp.2007.07061016 · DOI
- Sethi, 1986, Antianxiety effect of cannabis: Involvement of central benzodiazepine receptors, Biological Psychiatry, 21, 3, 10.1016/0006-3223(86)90003-X · DOI
- Stockings, 1947, A new euphoriant for depressive mental states, British Medical Journal, 1, 918, 10.1136/bmj.1.4512.918 · doi:10.1136/bmj.1.4512.918
- Swift, 2013, Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile, PloS one, 8, e70052, 10.1371/journal.pone.0070052 · DOI · Paper page
- Thomas, 2007, Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro, British Journal of Pharmacology, 150, 613, 10.1038/sj.bjp.0707133 · DOI · Paper page
- Valverde, 2012, CB1 receptor-deficient mice as a model for depression, Neuroscience, 204, 193, 10.1016/j.neuroscience.2011.09.031 · DOI
- Volkow, 2014, Adverse health effects of marijuana use, New England Journal of Medicine, 370, 2219, 10.1056/NEJMra1402309 · DOI · Paper page
- Wade, 2003, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms, Clinical Rehabilitation, 17, 21, 10.1191/0269215503cr581oa · DOI · Paper page
- Wall, 2011, Adolescent marijuana use from 2002 to 2008: Higher in states with medical marijuana laws, cause still unclear, Annals of Epidemiology, 21, 714, 10.1016/j.annepidem.2011.06.001 · DOI · Paper page
- Walsh, 2013, Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use, International Journal of Drug Policy, 24, 511, 10.1016/j.drugpo.2013.08.010 · DOI · Paper page
- Walsh, 2017, Medical cannabis and mental health: A guided systematic review, Clinical Psychology Review, 51, 15, 10.1016/j.cpr.2016.10.002 · DOI · Paper page
- Zuardi, 1982, Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects, Psychopharmacology, 76, 245, 10.1007/BF00432554 · DOI · Paper page
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 275
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Xue, S., Husain, M. I., Zhao, H., & Ravindran, A. V. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720952251 · Cited by 65
Addictive potential of novel treatments for refractory depression and anxiety
Kolar, D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167538 · Cited by 37
“On the other hand, cannabis is associated with adverse effects including increased anxiety, psychosis, cognitive impairment, and addiction, which pose significant limitations to using cannabis as a treatment in psychiatry.(36) The unjustified belief that medicinal cannabis may have anxiolytic effects comes from report…”
Influential
Metadata
- Authors
- Turna, J., Patterson, B., & Van Ameringen, M.
- Venue
- Depression and Anxiety
- Publisher
- Wiley
- Published
- 2017-06-21
- Volume
- 34
- Issue
- 11
- Pages
- 1006-1017
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2706778363
- Cited by
- 100
- References
- 29
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? https://app.cochat.ai/papers/10.1002/da.22664
- The paper
- Turna, J., Patterson, B., & Van Ameringen, M. (2017). Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depression and Anxiety. https://doi.org/10.1002/da.22664
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.